3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Breast
2
Sarcoma
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Conditions
Lymphoma
8
Lymphoma, Extranodal NK-T-Cell
6
Neoplasm Metastasis
3
Sarcoma
2
Lymphoma, Large B-Cell, Diffuse
2
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Liver Neoplasms
1
Immunoblastic Lymphadenopathy
1
Head and Neck Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
3
Sirolimus
2
Drug Therapy
2
Carboplatin
2
Blood Specimen Collection
2
spartalizumab
1
ixabepilone
1
fludarabine
1
etoposide phosphate
1
durvalumab
1
atezolizumab
1
advexin
1
Topotecan
1
Tissue Banks
1
Thiotepa
1
Radiotherapy
1
Quality of Life
1
Psychology, Positive
1
Psychiatric Rehabilitation
1
Patient Reported Outcome Measures
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Methods
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
Immunotherapy
1
Immunohistochemistry
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Neoplasms
×
spartalizumab
×
Lymphoid
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts